Abstract
We aimed to demonstrate the inflammation with local and systemic mediators, pre and post treatment differences between smoker and nonsmoker asthmatics by measuring IL-6, LTB4, LTD4, 8-isoprostane in EBC (exhaled breath condensate) and blood.
Nineteen newly diagnosed asthmatics' EBC and blood samples were taken, before and 3 months after treatment. ACT (asthma control test) was performed at third month control visit. IL-6, LTB4, LTD4, 8-isoprostane were measured in blood and EBC. Differences of these parameters between groups and the values before and after treatment were compared statistically.
Ten (52,6%) were nonsmokers, 9(47,4%) patients were still smoking (more than 1 pack/year and less than 10pack/years). Pretreatment blood and EBC IL-6, LTB4, LTD4, 8-isoprostane levels were compared between smoker and nonsmoker patients, significant difference was not found (p>0,05). Mean ACT of nonsmokers was significantly higher than smokers (23±1,88 versus 19±3,46), (p<0,05). There was no significant difference between smoker and nonsmoker groups about changes at the levels of pre and post treatment blood IL-6, LTB4, LTD4, 8-isoprostane and EBC IL-6, LTB4, LTD4 (p>0,05). The decrease of EBC 8-isoprostane levels was significantly higher at nonsmoker group (p<0,05). EBC IL-6 levels decreased after treatment, blood levels increased at smoking group, but it was not significant (p>0,05). EBC LTB4 increased at smoking group after treatment, LTD4 levels in blood increased in both groups, but statistical significance could not be found (p>0,05, p>0,05 ).
It seems difficult to predict the response to treatment at smoker asthmatics with these biomarkers in the study.
- © 2014 ERS
